AIM Vaccine Co., Ltd. (HKG: 6660)
Hong Kong
· Delayed Price · Currency is HKD 5.85
-0.15 (-2.50%)
Jan 3, 2025, 4:08 PM HKT
AIM Vaccine Revenue
AIM Vaccine had revenue of 537.18M CNY in the half year ending June 30, 2024, a decrease of -9.19%. This brings the company's revenue in the last twelve months to 1.18B, down -2.37% year-over-year. In the year 2023, AIM Vaccine had annual revenue of 1.19B, down -6.06%.
Revenue (ttm)
1.18B CNY
Revenue Growth
-2.37%
P/S Ratio
5.57
Revenue / Employee
729.17K CNY
Employees
1,624
Market Cap
7.08B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.19B | -76.61M | -6.06% |
| Dec 31, 2022 | 1.26B | -306.06M | -19.49% |
| Dec 31, 2021 | 1.57B | -67.84M | -4.14% |
| Dec 31, 2020 | 1.64B | 686.32M | 72.12% |
| Dec 31, 2019 | 951.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 26.04B |
| Hansoh Pharmaceutical Group Company | 13.00B |
| JD Health International | 58.84B |
| WuXi Biologics | 18.39B |
| Sinopharm Group | 634.32B |
| Innovent Biologics | 8.01B |
| Sino Biopharmaceutical | 29.86B |
| CSPC Pharmaceutical Group | 33.53B |